As of April 15, 2019, Qurin Diagnostics and Lionix International have acquired Surfix. As a supplier\nof custom-made nanocoatings, the capabilities of Surfix are highly\ncomplementary to the products and services offered by Qurin and LioniX\nInternational. The companies are already working together closely on early\ncancer detection and have realized a sensitive biochip, bringing together their\nrespective complementary technologies for this purpose. This acquisition\nstrengthens their relationship and mutual commitment towards bringing this\ntechnology to the global biomedical market.<\/p>\n\n\n\n
Molecular\n(\u201cDNA\u201d) diagnostics hold great promise for early diagnosis and personalized\nmedicine and has clear clinical added value. Nevertheless, market penetration\nfalls short of expectations, as the costs of current diagnostic platforms are\ntoo high. Currently available diagnostic platforms based on Polymerase Chain\nReaction and Next Generation Sequencing are very expensive, time consuming, and\nrequire extensive infrastructure and highly skilled personnel. A breakthrough\nis needed for the desired mass implementation of molecular diagnostics to\nrevolutionize medicine.<\/p>\n\n\n\n
Qurin has\nthe goal to realize a diagnostic test platform that will overcome these\nlimitations for the early detection and monitoring of cancer, using urine as a\nliquid biopsy. This platform uses the biophotonic sensor technology developed by\nLionix International and the nanocoatings of Surfix. With this acquisition, Qurin\nand LioniX International strengthen their technology position by adding\nSurfix\u2019s biofunctionalization technology to their portfolio.<\/p>\n\n\n\n